General Information of Drug (ID: DMPHXMI)

Drug Name
Besifloxacin Drug Info
Synonyms Besivance (TN)
Indication
Disease Entry ICD 11 Status REF
Ocular inflammation 9C61.24 Approved [1] , [2]
Cross-matching ID
PubChem CID
10178705
ChEBI ID
CHEBI:135622
CAS Number
CAS 141388-76-3
TTD Drug ID
DMPHXMI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [3]
Ciprofloxacin XR DM2NLS9 Bacterial infection 1A00-1C4Z Approved [4]
Levofloxacin DMS60RB Bacterial infection 1A00-1C4Z Approved [4]
Gatifloxacin DMSL679 Respiratory tract infection CA45 Approved [4]
Norfloxacin DMIZ6W2 Bacterial infection 1A00-1C4Z Approved [4]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [4]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [4]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [6]
Ofloxacin DM0VQN3 Bacterial infection 1A00-1C4Z Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciprofloxacin XR DM2NLS9 Bacterial infection 1A00-1C4Z Approved [4]
Levofloxacin DMS60RB Bacterial infection 1A00-1C4Z Approved [4]
Gatifloxacin DMSL679 Respiratory tract infection CA45 Approved [4]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [4]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [4]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [6]
Delafloxacin Meglumine DMVTU5Q Acute bacterial skin infection 1C41 Approved [7]
Moxifloxacin DMU8V4S Bacterial infection 1A00-1C4Z Approved [4]
Zabofloxacin DMEY1F3 Pneumonia CA40 Phase 3 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [1] , [2]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [1] , [2]

References

1 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
2 Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90.
3 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.